Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Advances in antibody-drug conjugates for breast cancer at ESMO 2022

Naoto Ueno • 10 Sep 2022
ESMO 2022
Breast Cancer Antibodies Sacituzumab govitecan Trastuzumab deruxtecan
DESTINY-Breast04 TROPiCS-02

Naoto Ueno, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses updates from TROPiCS-2 (NCT03901339) and DESTINY-Breast04 (NCT03734029), which both investigated antibody-drug conjugates for patients with breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Naoto Ueno

Importance of DNA repair pathway in therapeutic combination strategies
0:53
Importance of DNA repair pathway in therapeutic combination strategies
Naoto Ueno • 14 Sep 2024
DESTINY-Breast04: exploring T-DXd and IO combinations in HER2-low breast cancer
1:14
DESTINY-Breast04: exploring T-DXd and IO combinations in HER2-low breast cancer
Naoto Ueno • 14 Sep 2024
DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers
2:31
DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers
Naoto Ueno • 14 Sep 2024
Biomarker-based personalization for HER2-low breast cancer treatment in DESTINY-Breast04
0:45
Biomarker-based personalization for HER2-low breast cancer treatment in DESTINY-Breast04
Naoto Ueno • 14 Sep 2024

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals